catalyst
biosciences
reports
third
quarter
operating
financial
results
provides
corporate
update
south
san
francisco
globe
newswire
catalyst
biosciences
nasdaq
cbio
today
announced
operating
financial
results
third
quarter
ended
september
provided
corporate
update
third
quarter
focused
preparing
initiate
two
clinical
trials
marzaa
building
complement
programs
plan
enroll
patients
pivotal
phase
study
marzaa
treatment
bleeding
hemophilia
b
patients
inhibitors
initiate
phase
trial
marzaa
treatment
bleeding
factor
vii
deficiency
glanzmann
thrombasthenia
hemlibra
patients
end
year
said
nassim
usman
president
chief
executive
officer
catalyst
biosciences
addition
track
deliver
important
program
milestones
including
disclosing
development
candidate
systemic
complement
program
recent
milestones
complement
intellectual
property
united
states
patent
trademark
offices
issued
patent
covering
catalyst
portfolio
engineered
proteases
selectively
cleave
degrade
complement
factor
including
lead
candidate
cb
potential
treatment
dry
amd
currently
development
license
collaboration
agreement
biogen
modified
proteases
inhibit
complement
activation
potential
treat
multiple
diseases
complement
activation
plays
role
newly
issued
patent
provides
protection
least
expected
milestones
marzeptacog
alfa
activated
marzaa
subcutaneously
sq
administered
engineered
coagulation
factor
viia
fviia
enroll
first
patient
phase
trial
end
year
evaluating
efficacy
sq
marzaa
treat
episodic
bleeding
individuals
hemophilia
b
inhibitors
initiate
phase
trial
fvii
deficiency
glanzmann
thrombasthenia
hemlibra
patients
systemic
complement
announce
development
candidate
december
third
quarter
results
financial
highlights
cash
cash
equivalents
investments
september
million
research
development
expenses
million
million
three
months
ended
september
respectively
increase
million
increase
due
primarily
increase
million
personnel
facilities
costs
increase
million
preclinical
research
increase
million
clinical
manufacturing
costs
general
administrative
expenses
million
million
three
months
ended
september
respectively
increase
million
increase
due
primarily
increase
million
professional
services
increase
million
payroll
payroll
related
costs
partially
offset
decrease
million
indirect
employee
facilities
costs
interest
income
net
million
million
three
months
ended
september
respectively
decrease
million
decrease
primarily
due
decrease
interest
income
investments
net
loss
attributable
common
stockholders
three
months
ended
september
million
per
basic
diluted
share
compared
million
per
basic
diluted
share
prior
year
period
september
company
shares
common
stock
outstanding
catalyst
biosciences
catalyst
research
clinical
development
biopharmaceutical
company
focused
addressing
unmet
medical
needs
rare
hematologic
disorders
protease
engineering
platform
generated
two
clinical
programs
hemophilia
research
program
engineering
subcutaneous
sq
complement
inhibitors
discovery
stage
factor
ix
gene
therapy
construct
cb
hemophilia
b
partnered
preclinical
development
program
biogen
dry
macular
degeneration
amd
product
candidates
generated
protease
engineering
platform
improved
functionality
potency
allow
sq
administration
recombinant
coagulation
factors
complement
inhibitors
high
activity
gene
therapy
constructs
less
frequently
dosed
intravitreal
therapeutics
statements
press
release
contains
statements
involve
substantial
risks
uncertainties
statements
include
statements
catalyst
plans
enroll
first
patient
phase
trial
marzaa
initiate
phase
trial
marzaa
fvii
deficiency
glanzmann
thrombasthenia
hemlibra
patients
potential
marzaa
effectively
therapeutically
treat
hemophilia
subcutaneously
superiority
cb
gene
therapy
candidates
company
collaboration
biogen
development
commercialization
pegylated
cb
potential
treatment
geographic
dry
macular
degeneration
actual
results
events
could
differ
materially
plans
intentions
expectations
projections
disclosed
statements
various
important
factors
could
cause
actual
results
events
differ
materially
including
limited
risk
trials
studies
may
delayed
result
factors
trials
may
satisfactory
outcomes
additional
human
trials
replicate
results
earlier
trials
potential
adverse
effects
may
arise
testing
use
marzaa
including
generation
neutralizing
antibodies
risk
costs
required
develop
manufacture
company
products
higher
anticipated
including
result
delays
development
manufacturing
resulting
factors
risk
biogen
terminate
catalyst
agreement
competition
risks
described
risk
factors
section
company
quarterly
report
filed
securities
exchange
commission
november
filings
securities
exchange
commission
company
assume
obligation
update
statements
except
required
law
contact
ana
kapor
catalyst
biosciences
investors
catalyst
biosciences
condensed
consolidated
balance
sheets
thousands
except
share
per
share
amounts
september
december
unaudited
assets
current
assets
cash
cash
equivalents
investments
accounts
receivable
prepaid
current
assets
total
current
assets
investments
assets
noncurrent
assets
property
equipment
net
total
assets
liabilities
stockholders
equity
current
liabilities
accounts
payable
accrued
compensation
deferred
revenue
accrued
liabilities
operating
lease
liability
total
current
liabilities
operating
lease
liability
noncurrent
total
liabilities
stockholders
equity
preferred
stock
par
value
shares
authorized
zero
shares
issued
outstanding
common
stock
par
value
shares
authorized
shares
issued
outstanding
september
december
respectively
additional
capital
accumulated
comprehensive
income
accumulated
deficit
total
stockholders
equity
total
liabilities
stockholders
equity
accompanying
notes
integral
part
condensed
consolidated
financial
statements
catalyst
biosciences
condensed
consolidated
statements
operations
thousands
except
share
per
share
amounts
unaudited
three
months
ended
september
nine
months
ended
september
license
collaboration
license
collaboration
revenue
operating
expenses
cost
license
cost
collaboration
research
development
general
administrative
total
operating
expenses
loss
operations
interest
income
net
net
loss
net
loss
per
share
attributable
common
stockholders
basic
diluted
shares
used
compute
net
loss
per
share
attributable
common
stockholders
basic
diluted
accompanying
notes
integral
part
condensed
consolidated
financial
statements
